Assuming studies is required, the following results were found.

  • Tecfidera (dimethyl fumarate)

    having a severe allergic reaction to this drug, call 911. Hair loss Hair loss isn't a side effect that has occurred in studies of Tecfidera. However, some people who take Tecfidera have had hair loss. In one report, a woman who started taking Tecfidera...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    leader in neuroscience, today announced positive results for #ofatumumab (OMB157) from the Phase III ASCLEPIOS I and II studies. In both head-to-head studies, ofatumumab demonstrated superiority over Aubagio®* (teriflunomide) in patients with relapsing...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies-1
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    leader in neuroscience, today announced positive results for ofatumumab (OMB157) from the Phase III ASCLEPIOS I and II studies. In both head-to-head studies, ofatumumab demonstrated superiority over Aubagio®* (teriflunomide) in patients with relapsing...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies
  • Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 - Science

    multiple sclerosis (2, 3). IFNα/β also demonstrates considerable potential for toxicity, which became apparent in initial studies in rodents (4) and subsequent clinical experience in patients (5, 6). Thus, the production of and response to type I IFNs...

    https://mschristian.org/index.php/blog/severe-type-i-interferonopathy-and-unrestrained-interferon-signaling-due-to-a-homozygous-germline-mutation-in-stat2-science
  • Fooling nerve cells into acting normal

    Discovery could inform future studies related to spinal cord injuries, multiple sclerosis and epilepsy Date:Source:University of Missouri-ColumbiaSummary:Scientists have discovered that a neuron's own electrical signal, or voltage, can indicate whether...

    https://mschristian.org/index.php/blog/fooling-nerve-cells-into-acting-normal
  • Research on immune activity in MS

    to axons (the wire-like nerve fibers) that contributes to longer-term disability. Research on the immune system includes studies on:Understanding components of the immune system such as T cells, B cells, and antibodiesIdentifying new targets for...

    https://mschristian.org/index.php/blog/research-on-immune-activity-in-ms
  • Aubagio (teriflunomide)

    didn't worsen as quickly) a lower risk for new lesions (scar tissue) in the brain For specific information from these studies, see the "Aubagio uses" section. Aubagio generic Aubagio is currently available only as a brand-name medication. Aubagio...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

    Methods We measured NfL in blood samples from 589 patients with relapsing-remitting multiple sclerosis (from phase 3 studies of fingolimod vs placebo, FREEDOMS and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with...

    https://mschristian.org/index.php/blog/blood-neurofilament-light-chain-as-a-biomarker-of-ms-disease-activity-and-treatment-response
  • New insights into how immune system and inflammation play a role in PD

    periphery, particularly in the gastrointestinal tract. Taken together, all data, including human, animal, and microbiome studies, suggest quite strongly that individuals with an increased tendency for peripheral inflammation have a higher risk to...

    https://mschristian.org/index.php/blog/new-insights-into-how-immune-system-and-inflammation-play-a-role-in-pd
  • Researchers find possible causes for lacking of effective therapy for multiple sclerosis

    and clinical trials. In the process, the authors link the discussion of therapy targets with results from pharmacological studies conducted with cell culture and animal models, as well as current clinical studies. One disease, numerous mechanisms A...

    https://mschristian.org/index.php/blog/researchers-find-possible-causes-for-lacking-of-effective-therapy-for-multiple-sclerosis
  • Potential genetic markers of multiple sclerosis severity

    of the brain and immune systems -- by using DNA from MS patients along with high-tech retinal scanning. If further studies confirm the researcher's findings, reported in the September issue of Brain, the investigators say they could serve as markers for...

    https://mschristian.org/index.php/blog/potential-genetic-markers-of-multiple-sclerosis-severity
  • CMSC INforMS: Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says

    regard to attainment of accepted disability milestones was reported with a fairly wide variance comparing outcomes across studies,” its researchers wrote. But all “share an overall precarious picture of the prognosis for newly diagnosed patients,” they...

    https://mschristian.org/index.php/blog/cmsc-informs-use-of-dmts-changing-natural-history-of-relapsing-ms-study-says
  • Vitamin D no defense against dementia

    Iacopetta, PhD candidate at the University of Adelaide. Based on a systematic review of over 70 pre-clinical and clinical studies, Ms Iacopetta investigated the role of vitamin D across a wide range of neurodegenerative diseases. "Past studies had found...

    https://mschristian.org/index.php/blog/vitamin-d-no-defense-against-dementia
  • #ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds

    activity. Those guidelines recommend treatment be restarted within 8-12 weeks after the last dose pre-delivery. Prior studies suggested that Tysabri use over the first trimester of pregnancy is not tied to major fetal risks. However, the medicine can be...

    https://mschristian.org/index.php/blog/ectrims2019-tysabri-during-pregnancy-and-after-delivery-seems-safe-reduces-relapse-risk-study-finds
  • Do minerals play a role in development of multiple sclerosis?

    Some studies have suggested that minerals such as zinc and iron may play a role in how multiple sclerosis (MS) progresses, once people have been diagnosed with it. But little was known about whether zinc, iron and other minerals play a role in the...

    https://mschristian.org/index.php/blog/do-minerals-play-a-role-in-development-of-multiple-sclerosis
  • MS: High-strength MRI may predict disease progression

    lesions and, in this instance, it was able to detect many lesions that researchers have not been able to see in previous studies. Researchers used a powerful MRI scanner to monitor people with multiple sclerosis and found a link between the total volume...

    https://mschristian.org/index.php/blog/ms-high-strength-mri-may-predict-disease-progression-1
  • Research Project 3TR To Use Breath Biopsy, Improve Immune-mediated Disease Management - Technology Networks

    provide Breath Biopsy Collection Stations and Kits for the collection of breath samples, and analysis services for multiple studies that have been identified at this stage as suitable to include breath sampling, alongside clinical and physiological...

    https://mschristian.org/index.php/blog/research-project-3tr-to-use-breath-biopsy-improve-immune-mediated-disease-management-technology-networks
  • What Happened With a Once-Promising Alzheimer's Drug

    from September 2014 to October 2018; DAYBREAK-ALZ was a phase III trial of 78 weeks from July 2016 to September 2018. The studies were designed differently: "AMARANTH was designed to go for about 2 years; that was partly because we were enrolling mild...

    https://mschristian.org/index.php/blog/what-happened-with-a-once-promising-alzheimer-s-drug
  • Genmab A/S (GMAB) Detailed Results from Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing MS Presented at ECTRIMS - StreetInsider.com

    to access https://www.streetinsider.com/Corporate News/Genmab AS (GMAB) Detailed Results from Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing MS Presented at ECTRIMS/15912802.html from 204.152.211.44 on 2019-09-15 15:49:39...

    https://mschristian.org/index.php/blog/genmab-a-s-gmab-detailed-results-from-phase-iii-asclepios-i-ii-studies-of-ofatumumab-in-patients-with-relapsing-ms-presented-at-ectrims-streetinsider-com
  • Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis.

    paliperidone, and febuxostat emerged as the most promising repurposable agents for treating MS. Molecular docking studies indicated that desvenlafaxine, paliperidone, and febuxostat are likely to induce allosteric TRPA1 channel inhibition. Future in...

    https://mschristian.org/index.php/blog/computational-drug-repurposing-algorithm-targeting-trpa1-calcium-channel-as-a-potential-therapeutic-solution-for-multiple-sclerosis

Results 1 - 20 of 122
 
 

Follow Us on Twitter

Follow Us On Twitter - Image